112 related articles for article (PubMed ID: 12487104)
1. Model studies of cyclophosphamide resistance in human myeloid leukemia.
Andersson BS; Murray D
Cancer Treat Res; 2002; 112():211-35. PubMed ID: 12487104
[No Abstract] [Full Text] [Related]
2. Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines.
Friedman HS; Johnson SP; Colvin OM
Cancer Treat Res; 2002; 112():199-209. PubMed ID: 12481718
[No Abstract] [Full Text] [Related]
3. Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s).
Sládek NE
Cancer Treat Res; 2002; 112():161-75. PubMed ID: 12481716
[No Abstract] [Full Text] [Related]
4. Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance.
Richardson ME; Siemann DW
Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):789-95. PubMed ID: 9369124
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.
Chen G; Teicher BA; Frei E
Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973
[TBL] [Abstract][Full Text] [Related]
6. Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines.
Parsons PG; Lean J; Kable EP; Favier D; Khoo SK; Hurst T; Holmes RS; Bellet AJ
Biochem Pharmacol; 1990 Dec; 40(12):2641-9. PubMed ID: 2260988
[TBL] [Abstract][Full Text] [Related]
7. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer.
Tanner B; Hengstler JG; Dietrich B; Henrich M; Steinberg P; Weikel W; Meinert R; Kaina B; Oesch F; Knapstein PG
Gynecol Oncol; 1997 Apr; 65(1):54-62. PubMed ID: 9103391
[TBL] [Abstract][Full Text] [Related]
8. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens.
Sreerama L; Sládek NE
Cancer Chemother Pharmacol; 2001 Mar; 47(3):255-62. PubMed ID: 11320670
[TBL] [Abstract][Full Text] [Related]
9. The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues.
Andersson BS; Mroue M; Britten RA; Murray D
Cancer Res; 1994 Oct; 54(20):5394-400. PubMed ID: 7923171
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells.
Tsukamoto N; Chen J; Yoshida A
Blood Cells Mol Dis; 1998 Jun; 24(2):231-8. PubMed ID: 9714700
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?
Ludeman SM; Gamcsik MP
Cancer Treat Res; 2002; 112():177-97. PubMed ID: 12481717
[No Abstract] [Full Text] [Related]
12. Cyclophosphamide resistance in medulloblastoma.
Friedman HS; Colvin OM; Kaufmann SH; Ludeman SM; Bullock N; Bigner DD; Griffith OW
Cancer Res; 1992 Oct; 52(19):5373-8. PubMed ID: 1356617
[TBL] [Abstract][Full Text] [Related]
13. Resistance factors in colon cancer tissue and the adjacent normal colon tissue: glutathione S-transferases alpha and pi, glutathione and aldehyde dehydrogenase.
Hengstler JG; Böttger T; Tanner B; Dietrich B; Henrich M; Knapstein PG; Junginger T; Oesch F
Cancer Lett; 1998 Jun; 128(1):105-12. PubMed ID: 9652800
[TBL] [Abstract][Full Text] [Related]
14. Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance in vivo.
de Groot CJ; Martens AC; Hagenbeek A
Eur J Cancer; 1994; 30A(14):2137-43. PubMed ID: 7857714
[TBL] [Abstract][Full Text] [Related]
15. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia.
Hilton J
Cancer Res; 1984 Nov; 44(11):5156-60. PubMed ID: 6488175
[TBL] [Abstract][Full Text] [Related]
16. Influence of cell cycle on glutathione-S-transferase, selenium-dependent glutathione peroxidase, superoxide dismutase and glutathione levels in human myeloid leukaemia cell lines.
Tihan T; Chiba P; Eher R; Goebl R; Pernerstorfer T; Kraupp M; Kaiser E
Carcinogenesis; 1989 Sep; 10(9):1709-12. PubMed ID: 2766462
[TBL] [Abstract][Full Text] [Related]
17. Characterization of quinone reductase, glutathione and glutathione S-transferase in human myeloid cell lines: induction by 1,2-dithiole-3-thione and effects on hydroquinone-induced cytotoxicity.
Li Y; Lafuente A; Trush MA
Life Sci; 1994; 54(13):901-16. PubMed ID: 7511200
[TBL] [Abstract][Full Text] [Related]
18. Over-expression of glutathione S-transferases, DT-diaphorase and an apparently tumour-specific cytosolic class-3 aldehyde dehydrogenase by Warthin tumours and mucoepidermoid carcinomas of the human parotid gland.
Sreerama L; Sladek NE
Arch Oral Biol; 1996 Jun; 41(6):597-605. PubMed ID: 8937651
[TBL] [Abstract][Full Text] [Related]
19. Overexpression or polycyclic aromatic hydrocarbon-mediated induction of an apparently novel class 3 aldehyde dehydrogenase in human breast adenocarcinoma cells and its relationship to oxazaphosphorine-specific acquired resistance.
Sreerama L; Sladek NE
Adv Exp Med Biol; 1993; 328():99-113. PubMed ID: 8493945
[No Abstract] [Full Text] [Related]
20. Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line.
Andersson BS; Mroue M; Britten RA; Farquhar D; Murray D
Acta Oncol; 1995; 34(2):247-51. PubMed ID: 7718264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
